PROUD stands tall: delayed-start studies in Parkinson's disease. Lancet Neurol 2013;12:728-9.
Hauser, RA. 2013. “PROUD Stands Tall: Delayed-Start Studies in Parkinson’s Disease. Lancet Neurol 2013;12:728-9.”. Lancet Neurol.
Search
Search results
811 results found
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28:1838-46.
Stocchi, F, O Rascol, A Destee, N Hattori, RA Hauser, AE Lang, W Poewe, et al. 2013. “AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study. Mov Disord 2013;28:1838-46.”. Mov Disord.
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol 2012;71:40-8.
Goldman, SM, F Kamel, GW Ross, SA Jewell, GS Bhudhikanok, D Umbach, C Marras, et al. 2012. “Head Injury, α-Synuclein Rep1, and Parkinson’s Disease. Ann Neurol 2012;71:40-8.”. Ann Neurol.
Pramipexole ER Study Group. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol 2012;35:174-81.
Mizuno, Y, M Yamamoto, S Kuno, K Hasegawa, N Hattori, T Kagimura, A Sarashina, et al. 2012. “Pramipexole ER Study Group. Efficacy and Safety of Extended- versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-Dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. Clin Neuropharmacol 2012;35:174-81.”. Clin Neuropharmacol.
Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease. Mov Disord 2011;26:813-8.
Hauser, RA, P Auinger, and Parkinson Study Group. 2011. “Determination of Minimal Clinically Important Change in Early and Advanced Parkinson’s Disease. Mov Disord 2011;26:813-8.”. Mov Disord.
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 2018;17:804-822.
Charvin, D, R Medori, RA Hauser, and O Rascol. 2018. “Therapeutic Strategies for Parkinson Disease: Beyond Dopaminergic Drugs. Nat Rev Drug Discov 2018;17:804-822.”. Nat Rev Drug Discov.
KETAMINE: Neural-and network-level changes
Bharmauria, Vishal, Hamidreza Ramezanpour, Afef Ouelhazi, Yassine Yahia Belkacemi, Oliver Flouty, and Steohane Molotchnikoff. 2024. “KETAMINE: Neural-and Network-Level Changes”. Neuroscience.
Future treatments for Parkinson’s disease: surfing the PD pipeline
Hauser, RA. 2011. “Future Treatments for Parkinson’s Disease: Surfing the PD Pipeline”. Int J Neurosci.
Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration.
Cicchetti, F, S Saporta, RA Hauser, M Parent, M Saint-Pierre, PR Sandberg, XJ Li, et al. 2009. “Neural Transplants in Patients With Huntington’s Disease Undergo Disease-Like Neuronal Degeneration.”. Proc Natl Acad Sci USA.
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease
Hauser, RA, J Bronzova, C Sampaio, AE Lang, O Rascol, A Theeuwes, and SV Van De Witte. 2009. “Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients With Advanced Parkinson’s Disease”. Eur Neurol.